Scientific Reports found that the experimental oral therapy CKD-506 was able to suppress demyelination and reduce symptoms of multiple sclerosis in mouse models. The study's findings suggest that CKD-506 might be a possible therapy for multiple sclerosis."/> Scientific Reports found that the experimental oral therapy CKD-506 was able to suppress demyelination and reduce symptoms of multiple sclerosis in mouse models. The study's findings suggest that CKD-506 might be a possible therapy for multiple sclerosis."/> Demyelination, MS symptoms reduced by oral CKD-506

Demyelination, MS symptoms reduced by oral CKD-506

2021-07-30

A study published in Scientific Reports found that the experimental oral therapy CKD-506 was able to suppress demyelination and reduce symptoms of multiple sclerosis in mouse models. The study's findings suggest that CKD-506 might be a possible therapy for multiple sclerosis.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.